{"id":536450,"date":"2021-04-01T16:32:01","date_gmt":"2021-04-01T16:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=536450"},"modified":"2021-04-01T16:32:01","modified_gmt":"2021-04-01T16:32:01","slug":"antinuclear-antibody-test-market-size-is-likely-to-be-valued-at-usd-236-billion-by-2025-grand-view-research-inc","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/antinuclear-antibody-test-market-size-is-likely-to-be-valued-at-usd-236-billion-by-2025-grand-view-research-inc_536450.html","title":{"rendered":"Antinuclear Antibody Test Market Size Is Likely To Be Valued At USD 2.36 Billion By 2025 | Grand View Research, Inc."},"content":{"rendered":"
\"Antinuclear<\/a><\/p>\n
\n
“Grand View Research, Inc. \u2013 Market Research And Consulting.”<\/div>\n<\/div>\n<\/div>\n
According to Grand View Research, Inc., the Antinuclear Antibody Test Market remained unscathed during the ongoing Covid-19 pandemic and is showcasing a promising growth trend by 2025. The test is now widely employed for the careful evaluation of incidental skin changes as a dermatological manifestation of Covid-19 infection.<\/div>\n

The global antinuclear antibody test market<\/a><\/strong> size is expected to reach USD 2.36 billion<\/strong> by 2025<\/strong> and is projected to expand at a CAGR<\/strong> of 12.5%<\/strong> over the forecast period. Rising adoption of the ANA test and an increase in government initiatives to treat autoimmune disorders are the primary factors driving the market. Furthermore, the rising incidence of autoimmune disorders is set to fuel the growth from 2018 to 2025.<\/p>\n

From the point of view of rheumatology bioinformatic analyses, antinuclear antibody tests have gained a prominent demand to evaluate the role of SARS-CoV-2 in inflammatory and viral arthritis and are essential for diagnosis. The market experienced staggering growth in 2020 and continues to observe an upsurge in demand as studies reveal the correlation between the occurrence of viral arthritis and skin inflammation, thus making it vital to recognize the pathogenesis of COVID-19 and its clinical phenotypes. <\/p>\n

Antinuclear Antibody Test Market Highlights<\/strong><\/p>\n

• <\/strong>Based on products, reagents and assay kits was the leading segment in 2017 and is anticipated to register the fastest growth by 2025 owing to the high product adoption of in clinical and research settings<\/p>\n

•<\/strong> Based on technique, immunofluorescence assay accounted for the highest revenue share in 2017 owing to its high adoption compared to other available techniques<\/p>\n

•<\/strong> Based on application, rheumatoid arthritis segment is projected to grow at the fastest rate due to the increasing incidence of the disease<\/p>\n

•<\/strong> North America was the leading regional segment in 2017, on account of the high adoption of ANA testing, presence of a robust healthcare infrastructure, and patient awareness<\/p>\n

For Requesting a Sample Copy of This Report, Please Visit @ <\/strong>https:\/\/www.grandviewresearch.com\/industry-analysis\/antinuclear-antibody-ana-test-market\/request\/rs1<\/a><\/p>\n

Antinuclear Antibody Test Market Segmentation<\/strong><\/p>\n

Grand View Research has segmented the global antinuclear antibody test market on the basis of product, technique, application, end use, and region:<\/p>\n

Antinuclear Antibody Test Product Outlook (Revenue, USD Million, 2014 – 2025)<\/strong><\/p>\n

    •<\/strong> Reagents & Assay Kits
    •<\/strong> Systems
    •<\/strong> Software & Services <\/p>\n

Antinuclear Antibody Test Technique Outlook (Revenue, USD Million, 2014 – 2025)<\/strong><\/p>\n

    •<\/strong> ELISA
    •<\/strong> Immunofluorescence Assay
    •<\/strong> Multiplex Assay<\/p>\n

Antinuclear Antibody Test Application Outlook (Revenue, USD Million, 2014 – 2025)<\/strong><\/p>\n

    •<\/strong> Rheumatoid Arthritis
    •<\/strong> Systemic Lupus Erythematosus
    •<\/strong> Sjogren’s Syndrome
    •<\/strong> Scleroderma
    •<\/strong> Others<\/p>\n

Antinuclear Antibody Test End-use Outlook (Revenue, USD Million, 2014 – 2025)<\/strong><\/p>\n

    •<\/strong> Hospitals
    •<\/strong> Clinical Laboratories
    •<\/strong> Physician Office Laboratories
    •<\/strong> Others<\/p>\n

Antinuclear Antibody Test Regional Outlook (Revenue, USD Million, 2014 – 2025)<\/strong><\/p>\n

    •<\/strong> North America
        • The U.S.
        • Canada
    •<\/strong> Europe
        • Germany
        • U.K.
    •<\/strong> Asia Pacific
        • China
        • India
        • Japan
    •<\/strong> Latin America
        • Brazil
        • Mexico
    •<\/strong> Middle East & Africa
        • South Africa<\/p>\n

List of Key Players in Antinuclear Antibody Test Market<\/strong><\/p>\n